Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?
- PMID: 22780892
- PMCID: PMC3666916
- DOI: 10.1111/j.1537-2995.2012.03721.x
Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?
Comment on
-
Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.Transfusion. 2012 Jul;52(7):1482-9. doi: 10.1111/j.1537-2995.2011.03420.x. Epub 2011 Nov 2. Transfusion. 2012. PMID: 22043925 Clinical Trial.
References
-
- Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2011 - PubMed
-
- Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586–597. - PubMed
-
- Brown KE. The expanding range of parvoviruses which infect humans. Rev Med Virol. 2010;20:231–244. - PubMed
-
- Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfus Med. 2007;17:263–278. - PubMed
-
- Slavov SN, Kashima S, Pinto AC, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol. 2011;62:247–262. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
